Finance

Hyaluronidase maker approved for listing on American Stock Exchange

Published in Gene Therapy Weekly, November 25th, 2004

Halozyme Therapeutics, Inc., (HZYM), a development-stage biopharmaceutical company developing and commercializing recombinant human enzymes, announced that its common stock has been approved for listing on the American Stock Exchange (Amex).

Halozyme's common stock will trade under the symbol "HTI."

"We are very excited about moving to the American Stock Exchange. It is indicative of the significant progress that Halozyme has made over the past few months, including raising $13.9 million in a private placement, signing an exclusive sales and marketing agreement with Baxter Healthcare for our drug product, Enhanze SC, and filing a 510(k) application...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-11-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry